Want to join the conversation?
Colin Bristow of BofA asks about the Prevnar franchise; expectations going forward and biosimilar candidate. $PFE President Albert Bourla said that on Prevnar, in the US, the company has achieved 86% market share; 92% at retailers. In Europe, $PFE expects strong growth in 2016. On biosimilars, there are nine distinct molecules in different stages.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.